All posts by admin

Business Wire India

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement to exclusively license global rights to MIUDELLA, Sebela Pharmaceuticals’ hormone-free copper intrauterine device (IUD) contraceptive. The effectiveness of this transaction is subject to review under the Hart-Scott-Rodino Antitrust Improvements Act and to U.S. Food and Drug Administration (FDA) approval of MIUDELLA’s alternate supply chain entities and certain other conditions.

 

MIUDELLA, the first hormone-free copper IUD approved in the U.S. in the last 40 years, is complementary to Organon’s commercial capabilities and would further Organon’s commitment to building a portfolio of products that meet women’s diverse reproductive health needs. MIUDELLA was approved by the FDA on February 24, 2025, for the prevention of pregnancy in females of reproductive potential for up to three years and is not yet commercially available. MIUDELLA offers an additional option for women seeking long-acting, reversible, hormone-free contraception. MIUDELLA contains a unique flexible frame and a fully preloaded inserter with a small, tapered insertion tube diameter of 3.7mm.¹

 

Under the terms of the agreement, Organon will pay $27.5 million at closing, with potential sales-based milestone payments of up to $505 million, as well as tiered double-digit royalties based on net sales.

 

INDICATION FOR MIUDELLA®
MIUDELLA® is a copper-containing intrauterine system (IUS) indicated for prevention of pregnancy in females of reproductive potential for up to 3 years.

 

IMPORTANT SAFETY INFORMATION

 

• WARNING: Improper insertion of intrauterine systems, including MIUDELLA^®, increases the risk of complications.
• Proper training prior to first use of MIUDELLA^® can minimize the risk of improper insertion.
• MIUDELLA^® is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the MIUDELLA^® REMS program to ensure healthcare providers are trained on the proper insertion of MIUDELLA^® prior to first use. Further information is available at miudellarems.com and 1-855-337-0772.

 

CONTRAINDICATIONS:

• Use is contraindicated when one or more of the following conditions exist:
  • Pregnancy or suspicion of pregnancy, congenital or acquired abnormalities of the uterus, including leiomyomas, resulting in distortion of the uterine cavity, acute pelvic inflammatory disease (PID), postpartum endometritis or postabortal endometritis in the past 3 months, known or suspected uterine or cervical malignancy, for use as post-coital contraception (emergency contraception), uterine bleeding of unknown etiology, untreated acute cervicitis or vaginitis or other lower genital tract infection, conditions associated with increased susceptibility to pelvic infections, Wilson’s disease, a previously placed IUS that has not been removed, hypersensitivity to any component of MIUDELLA®, including polypropylene, copper, nitinol, an alloy of nickel and titanium, or any trace elements present in the copper components of MIUDELLA®. Persons with allergic reactions to these components may suffer an allergic reaction to this intrauterine system. Prior to placement, patients should be counseled on the materials contained in the IUS, as well as potential for allergy/hypersensitivity to these materials.

 

WARNINGS AND PRECAUTIONS:

• Risk of Complications Due to Improper Insertion: Improper insertion of intrauterine systems, including MIUDELLA®, increases the risk of perforation, infection, undiagnosed abnormal bleeding, pregnancy loss (if pregnancy occurs with MIUDELLA® in situ), and expulsion. Proper training prior to first use can minimize the risk of improper insertion. MIUDELLA® is available only through a restricted program under a REMS.
• MIUDELLA® REMS: MIUDELLA® is only available through a restricted program under a REMS called MIUDELLA® REMS Program to ensure all healthcare providers are trained prior to first use. Notable requirements include the following:
  • Healthcare providers must be certified with the program by enrolling and completing training on the proper insertion of MIUDELLA® prior to first use.
  • Pharmacies and healthcare settings that dispense MIUDELLA® must be certified by enrolling in the REMS and must only dispense MIUDELLA® to certified healthcare providers.
  • Further information is available at miudellarems.com and 1-855-337-0772.
• Ectopic Pregnancy: Promptly evaluate females who become pregnant for ectopic pregnancy while using MIUDELLA®.
• Intrauterine Pregnancy: Increased risk of spontaneous abortion, septic abortion, premature delivery, sepsis, septic shock, and death if pregnancy occurs. Remove MIUDELLA® if pregnancy occurs with MIUDELLA® in place and the thread ends are visible or can be retrieved from the cervical canal.
• Sepsis: Group A streptococcal infection has been reported following insertion of other IUSs; strict aseptic technique is essential during insertion.
• Pelvic Infection: Promptly evaluate patients with complaints of fever or lower abdominal pain after insertion of MIUDELLA®. Remove MIUDELLA® in cases of recurrent pelvic inflammatory disease or endometritis, or if an acute pelvic infection is severe or does not respond to treatment.
• Perforation: May reduce contraceptive effectiveness and require surgery. Risk is increased if inserted in postpartum and lactating females and may be increased if inserted in females with fixed, retroverted uteri or noninvoluted uteri. If perforation is suspected or occurs during placement, MIUDELLA® should be removed.
• Expulsion: Partial or complete expulsion may occur. Remove a partially expelled MIUDELLA®.
• Wilson’s Disease: MIUDELLA® may exacerbate Wilson’s disease, a rare genetic disease affecting copper excretion; therefore, the use of MIUDELLA® is contraindicated in females with Wilson’s disease.
• Bleeding Pattern Alterations: Menstrual bleeding may be altered and result in heavier and longer bleeding with spotting.
• MRI Safety Information: Patients using MIUDELLA® can be safely scanned with MRI only under certain conditions.
• Medical Diathermy: Medical equipment that contains high levels of Radiofrequency (RF) energy such as diathermy may cause health effects (by heating tissue) in females with a metal-containing IUS including MIUDELLA®. Avoid using high medical RF transmitter devices in females with MIUDELLA®.

 

ADVERSE REACTIONS: Most common adverse reactions (≥5%) are: heavy menstrual bleeding, dysmenorrhea, intermenstrual bleeding, pelvic discomfort, procedural pain, pelvic pain, post procedural hemorrhage, dyspareunia.

MIUDELLA® does not protect against human immunodeficiency virus (HIV) or other sexually transmitted infections (STIs).

 

Before prescribing MIUDELLA®, please read the full Prescribing Information, including Boxed Warning.

 

About Organon
Organon (NYSE: OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across Women’s Health and General Medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 markets.

 

Headquartered in Jersey City, New Jersey, Organon is committed to advancing access, affordability, and innovation in healthcare. Learn more at www.organon.com and follow us on LinkedIn, Instagram, X, YouTube, TikTok and Facebook.

 

Cautionary Note Regarding Forward-Looking Statements
Except for historical information, this press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about the potential benefits of Organon’s exclusive license of global rights to MIUDELLA^®. Forward-looking statements may be identified by words such as “will,” “potential,” “future,” “can,” “may,” “would,” or words of similar meaning. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate, or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include, but are not limited to, any review under the Hart-Scott-Rodino Antitrust Improvements Act, failure to secure FDA approval of MIUDELLA’s supply chain or otherwise satisfy the conditions of the transaction; weakening of economic conditions that could adversely affect the level of demand for MIUDELLA^®; pricing pressures globally, including rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to or affecting Medicare, Medicaid and healthcare reform, pharmaceutical pricing and reimbursement, access to the company’s products, international reference pricing, including most-favored-nation drug pricing, and other pricing related initiatives and policy efforts; the impact of tariffs and other trade restrictions or domestic sourcing requirements; expanded brand and class competition in the markets in which the company operates; the failure of any supplier to provide substances, materials, or services as agreed, or otherwise meet their obligations to the company; the increased cost of supply, manufacturing, packaging, and operations; difficulties developing and sustaining relationships with commercial counterparties, including Sebela Pharmaceuticals; the impact of higher selling and promotional costs; efficacy, safety or other quality concerns with respect to the company’s marketed products, whether or not scientifically justified, leading to product recalls, withdrawals, labeling changes or declining sales; future actions of third parties, including significant changes in customer relationships or changes in the behavior and spending patterns of purchasers of healthcare products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of physician visits and forgoing healthcare insurance coverage; the failure by the company or its third party collaborators and/or their suppliers to fulfill their or their regulatory or quality obligations; and volatility of commodity prices, fuel, and shipping rates that impact the costs and/or ability to supply the company’s products. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s filings with the SEC, including the company’s most recent Annual Report on Form 10-K and subsequent SEC filings (including amendments thereto), available at the SEC’s Internet site (www.sec.gov). References and links to websites have been provided for convenience, and the information contained on any such website is not a part of, or incorporated by reference into, this press release. Organon is not responsible for the contents of third-party websites.

 

__________________________________

1 Creinin MD, Gawron LM, Roe AH, et al.; Copper 175mm2 IUD Phase 3 Clinical Investigator Group. Three-year efficacy, safety, and tolerability outcomes from a phase 3 study of a low-dose copper intrauterine device. Contraception. 2024 Nov 22:110771. doi: 10.1016/j.contraception.2024.110771.

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260223700923/en/

 

Business Wire India

 

• Angelini Pharma secures exclusive global license rights to future identified drug targets
• Quiver receives undisclosed advance payment and is eligible for future milestone-dependent payments and royalties
• Collaboration further expands Angelini Pharma’s focus on brain health, building on its deep therapeutic expertise and drug development experience

 

Angelini Pharma, part of the privately owned Angelini Industries, and Quiver Bioscience (“Quiver”), a discovery technology and therapeutics company advancing programs for the treatment of central nervous system (CNS) disorders, announced today that they have entered into a collaboration and licensing agreement to advance novel therapeutics for genetic epilepsies. The collaboration brings together Quiver’s unique drug discovery capabilities, data assets, and AI models with Angelini Pharma’s established expertise in brain health and epilepsy drug development.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223465174/en/

 

 

Under the terms of the multi-year agreement, Quiver will receive an undisclosed advance payment and support for defined research activities along with additional licensing fees granting Angelini Pharma exclusive access to collaboration-generated data during the research term. Quiver is also eligible to receive additional milestones payments of up to $120 million and additional royalties upon Angelini’s election of drug targets identified through the collaboration.

 

 

“The prospects of our collaboration with Quiver Bioscience are very promising,” said Rafal Kaminski, MD, PhD, Chief Scientific Officer at Angelini Pharma.” The aim is to generate novel scientific insights on a scale and richness that has been unprecedented in this area of research. By applying cutting-edge technologies and advanced data analytics approaches, including AI, this partnership will generate a unique data set to inform the development of novel therapies in the future.”

 

 

In its latest collaboration, Angelini Pharma will leverage Quiver’s technology platform to break new grounds in deeper understanding a broad set of Developmental and Epileptic Encephalopathies (DEEs). DEEs are a group of rare diseases affecting children worldwide, causing a spectrum of neurodevelopmental symptoms and severe treatment-resistant seizures linked to genetic mutations. They are often caused by gene mutations, but functional and molecular consequences of such mutations are not well understood in most cases. Despite introduction of recently approved treatments for some DEEs, there is still a pressing unmet need for more effective therapies. Quiver Bioscience’s advanced platform uses human neuronal models coupled with single-cell transcriptomic resolution, optical electrophysiology, and AI to accelerate the discovery of precision therapies for these complex conditions. The ultimate goal of the partnership is to discover and develop differentiated therapeutics that can address multiple DEEs.

 

 

“We’re excited to embark on this collaboration with the excellent team at Angelini Pharma,” said Graham T. Dempsey, PhD, Co-founder and Chief Executive Officer at Quiver Bioscience. “Together we are pursuing a novel approach uniquely enabled by Quiver’s technology platform. By leveraging altered electrophysiology in response to genetic perturbations as the core neuronal classifier and integrating paired multi-modal data, we aim to link functional phenotypes with the underlying molecular drivers. We look forward to translating this science into new medicines for a disease area in urgent need of innovation.”

 

 

“This new partnership is another step forward to advance our strategic priorities, strengthen our global presence and potentially expand our pipeline of innovative medicines and promising candidates”, said Sergio Marullo di Condojanni, Chief Executive Officer at Angelini Pharma. “It follows a number of strategic acquisitions and collaboration agreements that we have entered over the course of the past two years and will further boost our leadership and portfolio in brain health”.

 

 

Destum Partners acted as transaction advisor to Quiver Bioscience.

 

 

About Quiver Bioscience

 

 

Quiver Bioscience is a technology-driven biotechnology company focused on accelerating discovery of empirically grounded, AI-driven therapeutics that deliver transformative value to patients with neurological disease. Quiver has built the first-of-its kind perturbation atlas of neuronal behavior using its proprietary Genomic Positioning System (GPS) platform, enabling precise target identification, functional validation, and safety assessment. Their empirical-in-a-loop approach integrates scalable human neuronal models, advanced single-cell optical electrophysiology and multi-omics techniques, with machine learning and surrogate models, to identify novel therapeutic targets and optimal candidate molecules. For information, including scientific publications describing the application of Quiver’s GPS platform to drug discovery, visit www.quiverbioscience.com.

 

 

About Angelini Pharma

 

 

Angelini Pharma is an international pharmaceutical company, part of the privately owned multi-business Angelini Industries. The Company researches, develops and commercializes health solutions with a focus on the areas of Brain Health, including Mental Health and Epilepsy, and Consumer Health. Founded in Italy at the beginning of the 20th century, Angelini Pharma operates directly in 20 countries, employing more than 3,000 people. Its products are marketed in over 70 countries through strategic alliances with leading international pharmaceutical groups. More information: https://www.angelinipharma.com.

 

 

About Angelini Industries

 

 

Angelini Industries is a multinational industrial group founded in Ancona in 1919 by Francesco Angelini. Today, Angelini Industries represents a solid and diversified industrial reality that employs approximately 5,800 employees and operates in 21 countries around the world with revenues of over 2 billion euros, generated in the health, industrial technology, and consumer goods sectors. A targeted investment strategy for growth; constant commitment to research and development; deep knowledge of markets and business sectors, make Angelini Industries one of the Italian companies of excellence in the sectors in which it operates. To learn more visit https://www.angeliniindustries.com.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260223465174/en/

 

Business Wire India

• Global commercial leader with 21 systems sold to 13 customers to date – including 4 out of the top 10 supercomputing centres globally.
• Industrial leader with 15 systems delivered (largest number publicly disclosed by selected quantum companies¹), 30+ computers built, own chip factory and quantum data centre.
• The transaction values IQM at a pre-money equity valuation of approximately USD 1.8 billion and makes IQM the first European quantum company to go public.
• With the close of this transaction, IQM’s cash position expected to exceed USD 450 million.²
• Significant business momentum, with at least USD 35 million³ 2025 revenue (unaudited) and over USD 100 million bookings / visibility as of year-end 2025.
• Strong commercial integrations with high-performance computing and enterprise platforms across the quantum/AI value chain such as NVIDIA, Hewlett Packard Enterprise, AWS, Toyo Corporation and Bechtle AG.
• Technical successes, achieving greater than 99.9% fidelity for single-qubit and two-qubit gates and readouts in their processors, and on track to deliver broad commercialization with the release of its next generation system, Halocene.

 

IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), today announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading provider of quantum computers.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223639678/en/

 

 

 

Headquartered in Finland, IQM is also considering a dual listing that would see the trading of IQM’s ordinary shares on the Helsinki stock exchange, which would be expected to take place following the completion of this transaction.

 

IQM is a quantum computing company that builds full stack, open-architecture systems that can be deployed on-premise or accessed via the cloud. IQM operates a vertically integrated business model, boasting a unique combination of proprietary infrastructure from their own chip design tool and software developer platform, to a quantum chip fab, assembly line and data centre, allowing the company to accelerate its innovation cycles, deliver best-in-class quantum computing to its customers and enabling the quantum ecosystem to grow.

 

 

Transaction Highlights:

 

 

Following completion of the transaction, IQM’s cash on its balance sheet is expected to be in excess of USD 450 million cash at closing⁴ (including IQM’s existing cash), providing runway for continued broad commercial advantage:

 

 

• Approximately USD 175 million of cash held in RAAQ’s trust account (based on the current amount in the trust account and assuming no redemptions);
• Approximately USD 134 million in proceeds from a PIPE financing at USD 10.00 per share from leading new and existing and institutional investors, to close concurrently with the business combination, subject to the satisfaction of certain customary closing conditions;
• Expected USD 24 million in proceeds from the cash exercise of outstanding IQM warrants prior to the closing;
• Existing cash on IQM’s balance sheet of USD 172 million (unaudited as of year-end 2025); and
• The transaction values IQM at a pre-money equity valuation of approximately USD 1.8 billion.

 

 

Jan Goetz, Co-Founder and Chief Executive Officer, IQM,said: “We built IQM from the beginning for one purpose — to put working quantum computers in the hands of the people who will use them to solve real problems. Not someday. Now. Quantum computing is a science project no more. It is an industry where customers own, operate, and build on advanced quantum computers. That’s what IQM makes possible.”

 

Peter Ort, Chief Executive Officer and Co-Chairman, Real Asset Acquisition Corp, said: “IQM has built and delivered more on-premises quantum systems than any other competitor⁵ — to some of the most demanding research institutions on earth. This transaction will accelerate the growth of a company that has already earned its position in the field, with real customers, running real quantum systems, today.”

 

 

Sierk Poetting, Chairman of IQM’s Board of Directors, said: “Going public is not a change of direction but is rather an acceleration. The board stands fully behind IQM’s mission and goals to make quantum infrastructure as foundational and accessible as classical computing.”

 

 

The existing IQM shareholders will not sell any shares or receive any cash consideration as part of the transaction and all material IQM shareholders have committed to a customary lock-up agreement at close of this transaction.

 

 

The board of directors of both IQM and RAAQ have each unanimously approved the proposed business combination. The closing of the proposed business combination is subject to, among other things, the approval by shareholders of RAAQ and IQM of the business combination agreement and the satisfaction of other customary closing conditions.

 

 

Additional information about the proposed business combination, including a copy of the business combination agreement, will be provided in a Current Report on Form 8-K to be filed by RAAQ with the Securities and Exchange Commission (the “SEC”).

 

 

The securities being sold in the PIPE financing have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws and accordingly may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.

 

 

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

 

 

Conference Call Information

 

 

Management of IQM and RAAQ will host an investor conference call to discuss the proposed transaction and review an investor presentation, with exact details to be updated and confirmed with a follow-up announcement. Interested investors will be able to access a recording of the conference call by visiting https://meetiqm.com/investors/. A transcript of the call will also be filed by RAAQ with the SEC.

 

 

Advisors

 

 

J.P. Morgan SE is serving as financial advisor and capital market advisor to IQM. J.P. Morgan Securities LLC and TD Cowen are serving as PIPE placement agents to IQM. Rothschild & Co. is serving as financial advisor and capital markets advisor to IQM’s and its Board of Directors. TD Cowen is serving as financial advisor and capital markets advisor to RAAQ. Cohen & Company Capital Markets is serving as a capital markets advisor to RAAQ. Cooley LLP and Borenius Attorneys Ltd are serving as legal advisors to IQM, and Perkins Coie LLP, Krogerus Attorneys Ltd and Conyers Dill & Pearman LLP are serving as legal advisors to RAAQ. DLA Piper LLP (US) is serving as legal advisor to J.P. Morgan Securities LLC and TD Cowen. The Blueshirt Group is serving as investor relations advisor to IQM.

 

 

About IQM Quantum Computers

 

 

IQM Finland Oy (“IQM”, “IQM Quantum Computers”, “Company”) is a global leader in superconducting quantum computers. IQM provides both on-premises full-stack quantum computers and a cloud platform to access its systems. IQM customers include leading high-performance computing centres, research laboratories, universities, and enterprises that require full access to quantum hardware and software. IQM has over 300 employees, with headquarters in Finland and a global presence including France, Germany, Italy, Japan, Poland, Saudi Arabia, Spain, Singapore, South Korea, Taiwan, UK and the United States.

 

 

About Real Asset Acquisition Corp.

 

 

Based in Princeton, NJ, Real Asset Acquisition Corp. is a Nasdaq-listed (Nasdaq: RAAQ) special purpose acquisition company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The RAAQ team includes seasoned quantum computing experts with deep technical and industry experience.

 

 

¹ Represent publicly announced on-premises deliveries from each of IBM, D-Wave, Pasqal, Rigetti, IonQ, OQC, Quandela, Anyon Systems, QuEra, Atom Computing and Quantinuum

 

 

²Inclusive of cash commitments in excess of $130M from the PIPE, in addition to approximately $24M from expected exercises of warrants prior to transaction close, in addition to cash proceeds of the RAAQ trust (assuming nil redemptions) and IQM existing cash as of 12/31/25, less expected transaction expenses of $25M

 

 

³ Exchange rate of EUR/USD of 1.174 as of December 31, 2025

 

 

⁴ Inclusive of cash commitments in excess of $130M from the PIPE, in addition to approximately $24M from expected exercises of warrants prior to transaction close, in addition to cash proceeds of the RAAQ trust (assuming nil redemptions) and IQM existing cash as of 12/31/25, less expected transaction expenses of $25M

 

 

⁵ Represent publicly announced on-premises deliveries from each of IBM, D-Wave, Pasqal, Rigetti, IonQ, OQC, Quandela, Anyon Systems, QuEra, Atom Computing and Quantinuum

 

 

Additional Information About the Proposed Transaction and Where to Find It

 

 

In connection with the proposed business combination, IQM intends to file with the SEC a registration statement on Form F-4 (the “Registration Statement”), which will include a preliminary proxy statement of RAAQ and a preliminary prospectus of IQM, and after the Registration Statement is declared effective by the SEC, RAAQ will mail the definitive proxy statement/prospectus relating to the proposed business combination to its shareholders as of a record date to be established for voting at the extraordinary general meeting of its shareholders (the “Extraordinary General Meeting”). The Registration Statement, including the proxy statement/prospectus contained therein, will contain important information about the proposed business combination and the other matters to be voted upon at the Extraordinary General Meeting. This communication does not contain all the information that should be considered concerning the proposed business combination and is not intended to provide the basis for any investment decision or any other decision in respect of such matters. RAAQ and IQM may also file other documents with the SEC regarding the proposed business combination. RAAQ’s shareholders and other interested persons are advised to read, when available, the Registration Statement, including the preliminary proxy statement/prospectus contained therein, the amendments thereto and the definitive proxy statement/prospectus and other documents filed in connection with the proposed business combination, as these materials will contain important information about RAAQ, IQM and the proposed business combination. Shareholders may obtain copies of the Registration Statement, including the preliminary or definitive proxy statement/prospectus contained therein, and the other documents filed or that will be filed by RAAQ and IQM with the SEC, once available, without charge, at the SEC’s website located at www.sec.gov.

 

 

Forward-Looking Statements

 

 

This communication includes “forward-looking statements” within the meaning of the U.S. federal securities laws and “forward-looking information” within the meaning of applicable non-U.S. securities laws (collectively, “forward-looking statements”). Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict” or similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements are based upon current estimates and assumptions that, while considered reasonable by IQM and its management, and RAAQ and its management, as the case may be, are inherently uncertain. These statements include: projections of market opportunity and market share; estimates of customer adoption rates and usage patterns; projections regarding the Company’s ability to commercialize new products and technologies; projections of development and commercialization costs and timelines; expectations regarding the Company’s ability to execute its business model and the expected financial benefits of such model; expectations regarding the Company’s ability to attract, retain and expand its customer base; the Company’s deployment of proceeds from capital raising transactions; the Company’s expectations concerning relationships with strategic partners, suppliers, governments, state-funded entities, regulatory bodies and other third parties; the Company’s ability to maintain, protect and enhance its intellectual property; future ventures or investments in companies, products, services or technologies; development of favorable regulations affecting the Company’s markets; the successful consummation and potential benefits of the proposed business combination and expectations related to its terms and timing; the stock exchanges on which the securities of the combined company are expected to trade; proceeds from the business combination and related PIPE; funds received by the combined company from RAAQ’s trust account and redemptions by RAAQ’s public shareholders; the Company’s ability to commercialize its hardware and software; the expectation that the Company is building the sovereign infrastructure that allows quantum ecosystems to grow; and the potential for the Company to increase in value.

 

 

These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions, many of which are beyond the control of the Company and RAAQ.

 

 

These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions that may cause the actual results of the combined company following the proposed transaction, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such statements. Such risks and uncertainties include: that the Company is pursuing an emerging technology, which faces significant technical challenges and may not achieve commercialization or market acceptance; the Company’s historical net losses and limited operating history; the Company’s expectations regarding future financial performance, capital requirements and unit economics; the Company’s use and reporting of business and operational metrics; the Company’s competitive landscape; the Company’s dependence on members of its senior management and its ability to attract and retain qualified personnel; the potential need for additional future financing; the Company’s concentration of revenue in contracts with government or state-funded entities; the Company’s ability to manage growth and expand its operations; potential future acquisitions or investments in companies, products, services or technologies; the Company’s reliance on strategic partners and other third parties; the Company’s ability to maintain, protect and defend its intellectual property rights; risks associated with privacy, data protection or cybersecurity incidents and related regulations; the use, rate of adoption and regulation of artificial intelligence and machine learning; uncertainty or changes with respect to laws and regulations; uncertainty or changes with respect to taxes, trade conditions and the macroeconomic environment; the combined company’s ability to maintain internal control over financial reporting and operate a public company; the possibility that required shareholder and regulatory approvals for the proposed transaction are delayed or are not obtained, which could adversely affect the combined company or the expected benefits of the proposed transaction; the risk that shareholders of RAAQ could elect to have their shares redeemed, leaving the combined company with insufficient cash to execute its business plans; the occurrence of any event, change or other circumstance that could give rise to the termination of the business combination agreement; the outcome of any legal proceedings or government investigations that may be commenced against the Company or RAAQ; failure to realize the anticipated benefits of the proposed transaction; the ability of IQM or the combined company to issue equity or equity-linked securities in connection with the proposed transaction or in the future; and other factors described in RAAQ’s and the Company’s filings with the SEC. These forward-looking statements are based on certain assumptions, including that none of the risks identified above materialize; that there are no unforeseen changes to economic and market conditions, and that no significant events occur outside the ordinary course of business. Additional information concerning these and other factors that may impact such forward-looking statements can be found in filings and potential filings by the Company, RAAQ or the combined company resulting from the proposed business combination with the SEC, including under the heading “Risk Factors.” If any of these risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. In addition, these statements reflect the expectations, plans and forecasts of the Company’s and RAAQ’s management as of the date of this communication; subsequent events and developments may cause their assessments to change. While the Company and RAAQ may elect to update these forward-looking statements at some point in the future, they specifically disclaim any obligation to do so, unless required by applicable securities laws. Accordingly, undue reliance should not be placed upon these statements.

 

 

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this communication, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements. An investment in RAAQ is not an investment in any of RAAQ’s founders’ or sponsors past investments, companies, or affiliated funds. The historical results of those investments are not indicative of future performance of RAAQ, which may differ materially from the performance of RAAQ’s founders’ or sponsors past investments.

 

 

Participants in the Solicitation

 

 

RAAQ, the Company and certain of their respective directors, executive officers and other members of management and employees may, under SEC rules, be deemed to be participants in the solicitation of proxies from RAAQ’s shareholders in connection with the proposed transaction. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of RAAQ’s shareholders in connection with the proposed transaction will be set forth in the Registration Statement, including the proxy statement/prospectus contained therein, when it is filed with the SEC. You can find more information about RAAQ’s directors and executive officers in RAAQ’s final prospectus related to its initial public offering filed with the SEC on May 15, 2025 and in the subsequent Quarterly Reports on Form 10-Q filed by RAAQ with the SEC. Shareholders, potential investors, and other interested persons should read the Registration Statement, including the proxy statement/prospectus contained therein, carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from the sources described above.

 

 

No Offer or Solicitation

 

 

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction, including any European Economic Area member state or the United Kingdom. This communication is not, and under no circumstances is to be construed as, a prospectus, an advertisement or a public offering of the securities described herein in the United States or any other jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or exemptions therefrom. Any potential dual listing of IQM’s ordinary shares on the Helsinki stock exchange referred to in this communication would be made by means of a prospectus as set out in the EU Prospectus Regulation. INVESTMENT IN ANY SECURITIES DESCRIBED HEREIN HAS NOT BEEN APPROVED BY THE SEC OR ANY OTHER REGULATORY AUTHORITY NOR HAS ANY AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF THE OFFERING OR THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED HEREIN. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260223639678/en/

 

Business Wire India

The latest research from Omdia reveals that the European smartphone market declined by 1% in 2025 to 134.2 million units, marking the end of a disruptive year defined by subdued demand and new regulations requiring eco-design and USB-C.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223432918/en/

 

 

Samsung remained Europe’s largest smartphone vendor, with shipments marginally growing to 46.6 million units. After a slow 1H25 caused by the absence of the Galaxy A0x series, Samsung bounced back in 2H25, particularly by leveraging a discounted version of the Galaxy A16 alongside strong momentum for the Galaxy A56, which was the top-selling model in Europe in 2025.

 

Apple grew 6% to 36.9 million in 2025, reaching a record-high 27% market share in Europe, as iPhone refresh demand surged, boosted by strong interest from both consumers and businesses. Its performance was particularly driven by iPhone 16, the Pro Max version of both iPhone 16 and iPhone 17, and iPhone 16e. Compared to other markets worldwide, iPhone 16e was among Apple’s top-shipping models, largely driven by it replacing iPhone 14 and earlier models, which were discontinued in late 2024 due to the USB-C regulation.

 

Xiaomi remained third in the ranking at 16% market share as it declined 1% to 21.8 million units, largely driven by its budget-friendly Redmi series. Towards the end of 2025, Xiaomi’s overseas expansion of the ‘new retail strategy’ reached Europe, highlighted by several Xiaomi Stores opening and the company’s wider ecosystem portfolio expanding.

 

Motorola remained fourth despite declining 5% to 7.7 million units. Its shipments dipped in 1H25 as demand remained subdued, but recovered with strong momentum in the second half, highlighted by double-digit growth in 4Q. Its resilient performance was driven by continued successful expansion in key markets, including Poland, Italy, Spain, and the UK.

 

HONOR climbed into Europe’s top five for the first time as it grew 4% to 3.8 million units, particularly by leveraging its affordable X-series. The higher X-series focus highlights an increased focus on growing share, presence and relevance within its key channel partners –helping to build a foundation to support its premium ambitions.

 

“Europe’s five largest smartphone vendors continued to gain combined share, reflecting the importance of scale for long-term success in the region,” commented Runar Bjorhovde, Senior Analyst at Omdia. “Even though shares continue to shift towards the largest players, fierce competition within the channel continues to reign across all markets, increasing the need to differentiate and understand how to most effectively capture customers. The fierce channel competition has also created a growing willingness amongst sales partners to introduce new vendors with attractive products and differentiated brands into their portfolios. Even though many vendors beyond the top 5 faced big hurdles last year, vivo, London-headquartered Nothing and Amsterdam-headquartered Fairphone grew by high double digits. These vendors are excellent examples that there are opportunities through strong differentiation even in such an established, mature and highly competitive region.”

 

“In 2026, concerns around memory pricing have created a challenging outlook. In Europe, which made up just 10.8% of all smartphones shipped worldwide in 2025, the biggest question is which vendors are most likely to prioritize the region if hit by price increases or supply shortages,” added Bjorhovde. “We expect the largest vendors to be more resilient due to their scale and price-band coverage. However, for many vendors, it will be critical to find the right balance between different regions and markets. Scaling a smartphone business within Europe can be very gradual and challenging, requiring consistent investment over time, making it very costly to scale back. Europe’s large premium segment makes it attractive to many vendors in the long-run alongside a less price-sensitive mass-market segment.”

 

“However, even in the face of short-term difficulties, capturing interest and demand from customers must be the top priority for all industry players. Both vendors and channel partners need to find key differentiation points, target core influence stages in the buying journey, and retain customers more effectively than ever before.”

 

Omdia’s analysts will be at Mobile World Congress 2026: Book a meeting or interview here to discuss these findings and more.

 

Europe (excl. Russia) smartphone shipments (market share and annual growth)   Omdia Smartphone Market Pulse: 4Q25
Vendor	4Q25 shipments (millions)	4Q25 market share	4Q24 shipments (millions)	4Q24 market share	Annual growth
Apple	13.4	34%	12.7	33%	6%
Samsung	12.4	31%	11.2	29%	10%
Xiaomi	5.5	14%	5.9	15%	-7%
Motorola	2.5	6%	2.2	6%	13%
HONOR	1.3	3%	1.0	3%	24%
Others	4.7	12%	5.8	14%	-17%
Total	39.8	100%	38.8	100%	3%
Note: Xiaomi includes Redmi and POCO. Percentages may not add up to 100% due to rounding. Source: Omdia Smartphone Horizon Service (sell-in shipments), February 2026

 

Europe (excl. Russia) smartphone shipments (market share and annual growth)   Omdia Smartphone Market Pulse: 2025
Vendor	2025 shipments	2025 market share	2024 shipments	2024 market share	Annual growth
Samsung	46.6	35%	46.4	34%	0%
Apple	36.9	27%	34.9	26%	6%
Xiaomi	21.8	16%	22.2	16%	-1%
Motorola	7.7	6%	8.0	6%	-5%
HONOR	3.8	3%	3.7	3%	4%
Others	17.4	13%	20.9	15%	-17%
Total	134.2	100%	136.1	100%	-1%
Note: Xiaomi includes Redmi and POCO. Percentages may not add up to 100% due to rounding. Source: Omdia Smartphone Horizon Service (sell-in shipments), February 2026

 

ABOUT OMDIA

 

Omdia, part of TechTarget, Inc. d/b/a Informa TechTarget (Nasdaq: TTGT), is a technology research and advisory group. Our deep knowledge of tech markets grounded in real conversations with industry leaders and hundreds of thousands of data points, make our market intelligence our clients’ strategic advantage. From R&D to ROI, we identify the greatest opportunities and move the industry forward.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260223432918/en/

 

Business Wire India

Lenovo™ expanded its ThinkEdge portfolio with a new generation of AI-driven edge computing solutions, including the compact and reliable ThinkEdge SE10n Gen 2, the AI-ready ThinkEdge SE30n Gen 2, the AI-powerhouse ThinkEdge SE60n Gen 2, and Lenovo’s first industrial all-in-one (AIO) Panel PC, the ThinkEdge SE50a.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223166717/en/

 

 

 

As enterprises push intelligence closer to operations to improve resilience, reduce latency, and keep sensitive data local, edge computing has become a critical layer between devices, infrastructure, and cloud. Lenovo’s ThinkEdge solutions are purpose-built, industrial-grade edge systems designed to run reliably in harsh, space-constrained environments where traditional servers or PCs are impractical.

 

Powered by Intel Core processors with scalable AI options, the fanless rugged lineup features industrial design ideal for 24/7 operation in factories and warehouses, seamless connectivity with options for Wi-Fi 6E, cellular connectivity and more. Backed by Lenovo’s global supply chain, long lifecycle support, and enterprise-grade services, ThinkEdge solutions are engineered not just to deploy at scale, but to operate consistently over years of continuous use.

 

 

“Edge computing is where we turn insights into outcomes, and our next-generation ThinkEdge solutions place the power of AI exactly where decision making happens,” says Marc Godin, Vice President & General Manager, WW OEM Solutions – IDG Commercial. “Powering real-world AI applications delivering real-time data means loss prevention and instant inventory insights in retail; visual inspection and predictive maintenance in manufacturing; imaging workflow support and operation insights in healthcare; and even crowd management and infrastructure monitoring in cities and venues.”

 

 

“Our latest ThinkEdge portfolio delivers a truly comprehensive suite of solutions designed with AI in mind, from intelligent gateways to high-performance edge computing systems,” states Sanjeev Menon, Vice President & General Manager, Desktop Computing Business. “AI at the edge must be intelligent, protected and manageable at scale, and our lineup delivers by combining the latest computing core components, critical manageability and protection capabilities, and vertical industry ruggedization to help customers turn insights into recommendations and action.”

 

 

Edge AI – More Adaptability and Less Latency

 

 

Lenovo’s newest ThinkEdge lineup delivers optimized on-device AI, enabling businesses to act faster while removing reliance on cloud connectivity, decreasing latency, strengthening data privacy, and lowering operational costs. Spanning lightweight gateways to high-performance AI edge systems and operator interfaces, the ThinkEdge portfolio integrates seamlessly into existing environments and can be remotely managed, allowing customers to start small and scale edge intelligence with confidence as their use cases evolve. The latest ThinkEdge portfolio includes:

 

 

• ThinkEdge SE10n Gen 2, a compact intelligent gateway that provides reliable mobile management where needed. Built for connectivity, data capture and lightweight edge analytics, the fanless nano gateway is easy to deploy and delivers essential performance for customers of all sizes without the commitment of large investments.
• ThinkEdge SE30n Gen 2, a versatile AI-ready gateway that turns data into decisions with real-time inferencing right next to the equipment. A rugged yet compact device built for real-world edge conditions, the fanless gateway optimizes the Intel Core processor to streamline device orchestration and fleet-level manageability for complex edge deployments.
• ThinkEdge SE60n Gen 2, a high-performance edge computer solution with AI capability that supports multi-camera vision, predictive analysis and autonomous workflows across industry and enterprise edge deployments. Powered by Intel Core Ultra processors with integrated AI accelerators delivering up to 97 TOPS, the device brings reliable edge AI to the most demanding conditions, including industry automation, commercial autonomous robots, smart retail, healthcare, transportation, and more.
• ThinkEdge SE50a, Lenovo’s first industrial all-in-one Panel PC that embeds local AI intelligence into operator stations, reducing complexity while enhancing visibility, control, and insight at the point of interaction. Built for demanding environments, the rugged AIO is available in three different sizes (12.1”, 15.6” or 21.5”). It can be expanded to fit individual needs and is Lenovo’s most intuitive interface for frontline operations.

 

With its latest ThinkEdge portfolio, Lenovo is extending AI from the data center to the point of action, helping businesses turn operational data into real-world outcomes at the edge.

 

Lenovo’s latest generation of ThinkEdge devices now on display at EuroShop 2026, a major international retail fair held in Düsseldorf, Germany from February 22^nd to 26^th. To experience a complete ecosystem of solutions, including 11 interactive demos, visit the Lenovo booth at Hall 6 A22.

 

 

Availability ¹

 

 

• Lenovo ThinkEdge SE10n Gen 2 will be available in select markets worldwide starting July 2026.
• Lenovo ThinkEdge SE30n Gen 2 will be available in select markets worldwide starting April 2026.
• Lenovo ThinkEdge SE50n Gen 1 will be available in select markets worldwide starting June 2026.
• Lenovo ThinkEdge SE60n Gen 2 will be available in select markets worldwide starting April 2026.

 

Visit the ThinkEdge web page to find out more or contact your local Lenovo sales representative.

 

¹ On-shelf dates and color options may vary by geography and products may only be available in select markets. All offers subject to availability. Lenovo reserves the right to alter product offerings, features and specifications at any time without notice.

 

 

About Lenovo

 

 

Lenovo is a US$69 billion revenue global technology powerhouse, ranked #196 in the Fortune Global 500, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company with a full-stack portfolio of AI-enabled, AI-ready, and AI-optimized devices (PCs, workstations, smartphones, tablets), infrastructure (server, storage, edge, high performance computing and software defined infrastructure), software, solutions, and services. Lenovo’s continued investment in world-changing innovation is building a more equitable, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992) (ADR: LNVGY). To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub.

 

 

LENOVO and THINKEDGE are trademarks of Lenovo. ©Intel, the Intel logo and other Intel marks are trademarks of Intel Corporation or its subsidiaries. Wi-Fi is a trademark of Wi-Fi Alliance. All other trademarks are the property of their respective owners. ©2026 Lenovo Group Limited. All rights reserved.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260223166717/en/

 

Business Wire India

Ookla^®, a global leader in connectivity intelligence, and Ericsson, a world leader in communications technology, demonstrate an innovative solution allowing users to measure and validate 5G network slicing performance. This collaboration marks a major milestone in the 5G-Advanced era, providing a way to validate the Quality of Experience (QoE) essential for the next generation of mobile applications and use cases.

 

Historically, measuring the performance of an individual network slice from a consumer or enterprise device has been a significant technical challenge. Traditional speed tests measure the default internet connection.

 

 

Through this collaboration, Ookla and Ericsson developed a methodology that enables the Speedtest app to identify and test specific network slices. This breakthrough demonstrates how Service Level Agreements (SLAs) for differentiated services can finally be verified in real-time by both consumers using the Speedtest app and service providers.

 

 

Crucially, this puts the power of verification directly into the hands of the consumer, allowing them to use the unique Speedtest app to independently validate that the performance they’ve purchased is being delivered as promised.

 

 

“Network slicing is no longer a future concept; it is a commercial reality. However, you cannot manage what you cannot measure,” said Tibor Rathonyi, Senior Advisor at Ookla. “Our work with Ericsson is a pivotal first step in providing the transparency needed to prove the value of these premium 5G services to both consumers and enterprises.”

 

 

As 5G Standalone (SA) deployments scale globally, network slicing has emerged as the critical catalyst for 5G monetization. The technology allows operators to create multiple virtual networks (slices) over a single physical infrastructure, each tailored to specific requirements:

 

 

• Ultra-low latency for gaming,
• High-bandwidth for 8K video streaming,
• Mission-critical reliability for industrial IoT and emergency services.

 

MWC 2026 Live Demonstration

 

The results of this collaboration between Ookla and Ericsson will debut during Mobile World Congress (MWC) Barcelona 2026. Attendees can visit the Ericsson pavilion, in Hall 2, to experience a live demonstration of a specialized test version of the Speedtest® app, featuring:

 

 

• Side-by-Side Comparison: Visualizing the performance gap between a standard 5G connection and a service-specific slice within Ericsson’s live 5G network at the venue.
• SLA Verification: Real-time reporting on Key Performance Indicators (KPIs) within a dedicated slice to prove guaranteed quality of service.

 

About Ookla®

 

Ookla, a global leader in connectivity intelligence, brings together the trusted expertise of Speedtest®, Downdetector®, Ekahau®, and RootMetrics® to deliver unmatched network and connectivity insights. By combining multi-source data with industry-leading expertise, we transform network performance metrics into strategic, actionable insights.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260223609962/en/

 

Business Wire India

Reltio®, the leader in context intelligence, today announced it has earned the Azure Certified Software designation. This distinction validates that Reltio Data Cloud meets Microsoft’s rigorous standards for security, reliability, and performance, enabling enterprises to confidently unify their data estates and fuel their AI agents with trusted, real-time business context.

 

The certification reinforces the value of Reltio’s long-standing availability on the Microsoft Azure Marketplace. By accessing Reltio Data Cloud through the Marketplace, Azure customers can streamline procurement and count their Reltio investment toward their Microsoft Azure Consumption Commitment (MACC), simplifying budgeting and accelerating time-to-value.

 

 

“Achieving Microsoft Azure certification is a significant milestone for Reltio and a testament to our commitment to providing secure, seamless, and high-performance data solutions for enterprise customers,” said Manish Sood, CEO and Founder of Reltio. “This recognition validates Reltio’s architecture and capabilities and enables us to deliver unified data and real-time data intelligence supporting AI and digital transformation initiatives of businesses using Microsoft Azure.”

 

 

Easier Access to a Carefully Vetted Industry Data Solution for Azure Customers

 

 

To secure the Microsoft Azure certification, Reltio went through a rigorous technical and business review in which it demonstrated its Certification makes it easier for Azure clients to work with Reltio and access its vetted solutions within the Azure environment, providing a seamless, secure experience.

 

 

The Azure Certified Software status assures buyers that Reltio is fully compatible with the Azure ecosystem, including specific integrations that accelerate AI readiness, such as Microsoft Fabric, which enables zero-copy data sharing for direct access to unified data without complex ETL, and Microsoft Purview, which deeply integrates data quality insights for end-to-end governance visibility.

 

 

Proven Innovator in Data Governance and Context Intelligence

 

 

Reltio works closely with customers to unify and govern their data to deliver context intelligence across their enterprise, enabling better decision-making. As the first cloud-based data management technology company, Reltio has over a decade of experience working with business customers in key industries, including life sciences, financial services, hospitality and manufacturing, to help them achieve their goals.

 

 

Reltio is available on the Microsoft Azure Marketplace. To learn more about Reltio’s expertise, visit www.reltio.com.

 

 

About Reltio

 

 

Reltio (reltio.com), a leader in real-time data intelligence, believes data is the key to powering your organization’s success in the AI era. Reltio Data Cloud is the agentic data fabric for enterprise, powering real-time data intelligence and AI transformation with enterprise-grade security and governance. Our AI-native platform delivers unified, trusted, and context-rich data across domains through secure, governed pipelines. Organizations gain 360-degree views of their customers, products, suppliers, and other critical data sets, mobilized in milliseconds to any application, user, or AI agent. Trusted by the world’s largest organizations, including those in regulated industries, Reltio helps fuel frictionless operations, reduce risk with robust data protection, and drive innovation.

 

 

“Reltio” is a registered trademark, and “Reltio AgentFlow” and “Reltio Data Cloud” are each trademarks of Reltio, Inc. All Rights Reserved.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260223808668/en/

 

Business Wire India

 

As AI adoption gained momentum during the 2026 Chinese New Year, Ant Group announced today that both Alipay AI Pay and its AI health app AQ have each surpassed the 100 million user milestone.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223266559/en/

 

 

 

AI Payment Adoption Accelerates amid CNY AI Shopping Boom

 

From ordering bubble tea and coffee to buying movie tickets, Chinese consumers embraced AI-powered services in everyday scenarios during this year’s holiday, driving a surge in Alipay AI Pay usage.

 

 

Alipay AI Pay has surpassed 100 million users on February 23, becoming the world’s first AI-native payment product to reach this milestone. This surge highlights the broad commercial adoption of AI-powered payments. During the week of February 5-11, Alipay AI Pay processed over 120 million transactions.

 

 

Launched in 2025, Alipay AI Pay is an innovative payment solution that enables secure and seamless transactions through AI agents. By allowing consumers to pay via voice command and eliminating the need to switch between pages, Alipay AI Pay delivers a frictionless and more intuitive payment experience.

 

 

As agentic commerce accelerates in China, Alipay AI Pay has expanded into various use cases, including AI agents in apps and mini programs for brick-and-mortar retailers like Luckin Coffee, as well as AI smart glasses like Rokid and Alibaba’s consumer-facing AI application Qwen.

 

 

AQ Becomes the World’s Largest AI-Native Health App

 

 

This Chinese New Year, AQ gained traction through word of mouth and a series of marketing initiatives. During the holiday period, the standalone AQ app surpassed 100 million total users, making it the world’s largest AI-native health app.

 

 

A standout trend during the holiday was young people returning to their hometowns and introducing AQ to their families. Data shows that between February 9 and February 21, 52% of new users came from third-tier cities and below, highlighting the app’s rapid expansion beyond major urban centers. The most frequently used features included health Q&A, AI skin analysis, voice call consultations, personalized health goals, and digital health records.

 

 

This momentum translated into a sharp rise in downloads, with AQ ranking No. 1 on China’s Apple App Store overall download chart for several consecutive days during the holiday period.

 

 

In China, using AI to manage personal health is becoming increasingly common during both everyday life and during travel. According to AQ app data, usage among Chinese users traveling overseas during the holiday period from February 9 to February 21 increased by 106% compared with the same period in January prior to the holiday. Travelers relied on AQ to manage potential health concerns, including discomfort caused by changes in climate, diet, and environment.

 

 

A Focused AI Strategy

 

 

These milestones build on Ant Group’s distinctive AI strategy. While many companies compete for general-purpose AI entry points, Ant has focused on specialized, high-barrier sectors such as payments and healthcare—areas that demand deep expertise and, above all, user trust.

 

 

This approach is a natural extension of Ant Group’s business philosophy over the past two decades: leveraging technology to solve real-world livelihood challenges in specific scenarios, meeting societal needs while building durable competitive advantages.

 

 

About Ant Group

 

 

Ant Group is a global digital technology provider and the operator of Alipay, a leading internet services platform in China, connecting over one billion users to more than 10,000 types of consumer services from partners. Through innovative products and solutions powered by AI, blockchain and other technologies, Ant Group supports partners across industries to thrive through digital transformation in an ecosystem for inclusive and sustainable development. For more information, visit www.antgroup.com.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260223266559/en/

 

Business Wire India

Gold is more than just jewellery in India—it is a powerful financial asset that can help meet both planned and unexpected expenses. Bajaj Finance brings this potential to life with the Bajaj Finserv Gold Loan, offering quick approvals, competitive interest rates, and minimal documentation for borrowers. This festive season, the Gold Loan Carnival, running from 25th November 2025 to 28th February 2026, adds an extra layer of excitement, with exclusive rewards and benefits that make borrowing smarter, faster, and more rewarding. It is the perfect opportunity for individuals to make the most of their gold while making informed financial decisions.

Understanding gold loan interest rates

The gold loan interest rates are influenced by several key factors. The purity and value of the pledged gold directly impact the loan amount and applicable interest. Higher gold prices typically allow borrowers to secure larger loans at the same gold weight. Other elements, such as repayment tenure, prevailing market conditions, and economic trends, also shape interest rates. Bajaj Finserv Gold Loan provides transparent and competitive rates, ensuring borrowers can manage repayments effectively while leveraging their gold assets responsibly. Regular monitoring of gold prices helps borrowers determine the optimal time to take a loan.

What is a gold loan and its advantages

To understand what is gold loan, it is essentially a secured loan where gold jewellery serves as collateral. This security allows faster approvals and higher loan amounts compared to unsecured loans. Bajaj Finance offers a simple application process for Bajaj Finserv Gold Loan, either online via the app or website, or at any of its 1,100+ branches. Minimal documentation, such as Aadhaar, voter ID, or passport, is required. Borrowers also benefit from features like part-release of gold, secure storage in monitored vaults, and complimentary insurance, making gold loans a convenient and transparent financial solution.

Repayment tenure and its impact on interest

Repayment tenure is a key factor in determining the overall cost of a gold loan. Bajaj Finance offers options to pay interest monthly, bi-monthly, quarterly, half-yearly, or annually, with principal repayment at the end of the tenure. Borrowers can also prepay or foreclose their loans without any additional charges. Selecting a tenure aligned with personal financial circumstances allows borrowers to manage repayments efficiently and plan expenses effectively, ensuring a stress-free borrowing experience.

Gold Loan Carnival: rewards and benefits

The Gold Loan Carnival offers additional incentives for borrowers. Customers who avail a Bajaj Finserv Gold Loan of Rs. 1,00,000 or above during the offer period are eligible for rewards, provided the loan is not repaid within 180 days. Each customer can claim a reward only once. The rewards include a foreign travel voucher, a 42” LED TV, microwaves, and small electric appliances. This initiative allows borrowers to not only access quick funds but also enjoy festive benefits, making gold loans an attractive option for financial planning.

Seamless application process

Applying for a Bajaj Finserv Gold Loan is quick and straightforward. Borrowers can visit the nearest branch with their gold and KYC documents or apply online from the comfort of their home. The pledged gold is valued based on the prevailing gold price today, after which the loan amount is approved and disbursed, often within a single branch visit. Combined with competitive interest rates, secure gold storage, and insurance, the process ensures an efficient and reliable borrowing experience.

To apply online, follow these steps below:

• Start the application online through the Bajaj Finserv website or app.
• Enter the 10-digit mobile number and verify with OTP.
• Fill in the personal details and choose the nearest gold loan branch.
• Download the in-principle eligibility letter.

Business Wire India

Between 27 and 36 million¹ people in Europe are living with a rare disease, yet only around six percent currently have access to an approved treatment². Progress in diagnosis and treatment is often slowed by knowledge gaps, including the lack of clear, reliable, and patient-friendly information needed to support informed decision-making. Drawing on 30 years of experience in researching and developing therapies for rare diseases, AOP Health underscores the importance of collaboration across the healthcare community. On Rare Disease Day 2026, the company joins healthcare professionals, researchers and patient representatives in highlighting the need for closer cooperation to generate, share and better use scarce data to improve care for people living with rare diseases.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223167500/en/

 

 

 

“Working in rare diseases since 1996 has shown us that innovation is never a solo effort,” emphasized Melissa Fellner, Vice President Global Therapeutic Areas at AOP Health. “It requires continuous investment in data, open collaboration and information that reaches patients in a form they can use.”

 

Consistent with this approach, AOP Health is conducting five clinical studies in the field of rare diseases. The company collaborates with researchers at numerous renowned international universities, as well as 58 patient organizations, most of which focus on rare diseases. These partnerships aim to leverage synergies and to strengthen the evidence base.

 

 

Collaboration is key

 

 

Prof. Dr. med. Haifa Kathrin Al-Ali, a professor of internal medicine at Halle (Saale) University Hospital and Director of the Krukenberg Cancer Center Halle, shares AOP Health’s perspectives. ” Without informed patients, it is difficult to generate evidence that truly represents daily clinical reality,” she said. “Close collaboration and an exchange on equal footing are therefore essential, especially in rare diseases.”

 

 

Thus, cooperation between physicians, patients and the pharmaceutical industry plays a crucial role in advancing research.

 

 

New EU regulations require informed patients

 

 

Furthermore, patient involvement is becoming increasingly central to European evaluation and decision-making processes. New frameworks, such as joint clinical assessments (JCAs), and structured evaluation approaches, such as PICO (which defines populations, comparators, and patient-relevant outcomes), explicitly rely on evidence that reflects real-world needs and experiences. Therefore, robust, patient-relevant data and informed patient perspectives are becoming increasingly critical.

 

 

However, meaningful patient participation in these processes requires access to appropriate knowledge and competencies. Eva Otter, Vice President of PHA Europe, a patient advocacy group representing people living with pulmonary hypertension globally emphasizes, “To meet European requirements and participate effectively in evaluation processes, we need access to reliable, evidence-based information presented in a language we can understand. Patient-friendly expert information is therefore not an add-on, but a prerequisite for informed participation and credible assessments.”

 

 

Rare Disease Day 2026: Extending access to patient-centred information

 

 

To coincide with Rare Disease Day 2026, AOP Health is releasing a new episode of its German-language patient podcast to support patients in processing their diagnosis. This episode focuses on health literacy and addresses a central question: How can patients become well-informed and actively engaged in their care?

 

 

Links

 

 

Take a look at aop-health.com from 26.2.-2.3.2026 for a Rare Disease Day special and listen to the podcast „Ab jetzt ist alles anders? Leben nach und mit einer schwerwiegenden Diagnose“. (“Everything’s Different Now? Life After and With a Serious Diagnosis”) here.

 

 

About AOP Health

 

 

AOP Health is a global enterprise group with roots in Austria, where the headquarters of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) is located. Since 1996, the AOP Health Group has been dedicated to developing innovative solutions to address unmet medical needs, particularly in the fields of rare diseases and intensive care medicine. The group has established itself internationally as a pioneer in integrated therapy solutions and operates worldwide through subsidiaries, representations, and a strong network of partners. With the claim “Needs. Science. Trust.” the AOP Health Group emphasizes its commitment to research and development, as well as the importance of building relationships with physicians and patient advocacy groups to ensure that the needs of these stakeholders are reflected in all aspects of the company’s actions. (aop-health.com)

 

 

¹https://health.ec.europa.eu/european-reference-networks/rare-diseases_en
²https://www.eurordis.org/rare-disease-policy/european-policy/

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260223167500/en/